Fertility Market Poised For Growth Spurt After Fallow Decade
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Late-stage pipeline is dominated by follicle stimulating hormones, split between “biobetters” and biosimilars. Next-generation oxytocin antagonists are leading candidates for the next novel entities in infertility.